title: Hormone treatment, estrogen receptor polymorphisms and mortality: a prospective cohort study.
abstract: BACKGROUND
  The association between hormone treatment (HT) and mortality remains controversial. This study aimed to determine whether the risk of mortality associated with HT use varies depending on the specific characteristics of treatment and genetic variability in terms of the estrogen receptor.
  
  
  RESULTS
  A prospective, population-based study of 5135 women aged 65 years and older who were recruited from three cities in France and followed over six years. Detailed information related to HT use was obtained and five estrogen receptor polymorphisms were genotyped. The total follow-up was 25,436 person-years and during this time 352 women died. Cancer (36.4%) and cardiovascular disease (19.3%) were the major causes of death. Cox proportional hazards models adjusted for age, education, centre, living situation, comorbidity, depression, physical and mental incapacities, indicated no significant association between HT and mortality, regardless of the type or duration of treatment, or the age at initiation. However, the association between HT and all-cause or cancer-related mortality varied across women, with significant interactions identified with three estrogen receptor polymorphisms (p-values = 0.004 to 0.03) in adjusted analyses. Women carrying the C allele of ESR1 rs2234693 had a decreased risk of all-cause mortality with HT (HR: 0.42, 95% CI: 0.18-0.97), while in stark contrast, those homozygous for the T allele had a significantly increased risk of cancer-related mortality (HR: 3.18, 95% CI: 1.23-8.20). The findings were similar for ESR1 rs9340799 and ESR2 rs1271572.
  
  
  CONCLUSIONS
  The risk of mortality was not associated with HT duration, type or age at initiation. It was however not equal across all women, with some women appearing genetically more vulnerable to the effects of HT in terms of their estrogen receptor genotype. These findings, if confirmed in another independent study, may help explain the differential susceptibility of women to the beneficial or adverse effects of HT.
authors.affiliation: Inserm U1061, Université Montpellier 1, Montpellier, France. joanne.ryan@inserm.fr
authors.forename: Joanne
authors.initials: J
authors.lastname: Ryan
authors.forename: Marianne
authors.initials: M
authors.lastname: Canonico
authors.forename: Laure
authors.initials: L
authors.lastname: Carcaillon
authors.forename: Isabelle
authors.initials: I
authors.lastname: Carrière
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Scali
authors.forename: Jean-Francois
authors.initials: JF
authors.lastname: Dartigues
authors.forename: Carole
authors.initials: C
authors.lastname: Dufouil
authors.forename: Karen
authors.initials: K
authors.lastname: Ritchie
authors.forename: Pierre-Yves
authors.initials: PY
authors.lastname: Scarabin
authors.forename: Marie-Laure
authors.initials: ML
authors.lastname: Ancelin
mesh_terms: D000368:Aged; D005260:Female; D020249:Hormone Replacement Therapy; D006801:Humans; D009026:Mortality; D011110:Polymorphism, Genetic; D011446:Prospective Studies; D011960:Receptors, Estrogen / Q000235:genetics*
chemical_list: D011960:Receptors, Estrogen